Author

Javier Pérez Gisbert

REAL WORLD EFFECTIVENESS AND SAFETY OF VEDOLIZUMAB IN CROHN’S DISEASE WHEN USED AS A FIRST BIOLOGIC OR AFTER FAILURE OF ONE PREVIOUS ANTI-TNF (EVOLVE-IB STUDY)
REAL WORLD EFFECTIVENESS AND SAFETY OF VEDOLIZUMAB IN CROHN’S DISEASE WHEN USED AS A FIRST BIOLOGIC OR AFTER FAILURE OF ONE PREVIOUS ANTI-TNF (EVOLVE-IB STUDY)

Javier Pérez Gisbert  et al.

OBSERVATIONAL STUDY ON THE EFFECTIVENESS AND SAFETY OF VEDOLIZUMAB IN AN ULCERATIVE COLITIS POPULATION COMPRISED BY BIO-NAÏVE PATIENTS AND PATIENTS WITH FAILURE OF ONE PREVIOUS ANTI-TNF (EVOLVE-IB STUDY)
OBSERVATIONAL STUDY ON THE EFFECTIVENESS AND SAFETY OF VEDOLIZUMAB IN AN ULCERATIVE COLITIS POPULATION COMPRISED BY BIO-NAÏVE PATIENTS AND PATIENTS WITH FAILURE OF ONE PREVIOUS ANTI-TNF (EVOLVE-IB STUDY)

Javier Pérez Gisbert  et al.

EFFECTIVENESS AND SAFETY OF USTEKINUMAB (UST) IN PATIENTS WITH ACTIVE CROHN'S DISEASE (CD) IN REAL LIFE: SUSTAIN STUDY
EFFECTIVENESS AND SAFETY OF USTEKINUMAB (UST) IN PATIENTS WITH ACTIVE CROHN'S DISEASE (CD) IN REAL LIFE: SUSTAIN STUDY

Javier Pérez Gisbert  et al.

LONG-TERM DURABILITY AND SAFETY OF USTEKINUMAB (UST) IN PATIENTS WITH ACTIVE CROHN'S DISEASE (CD) IN REAL LIFE: SUSTAIN STUDY
LONG-TERM DURABILITY AND SAFETY OF USTEKINUMAB (UST) IN PATIENTS WITH ACTIVE CROHN'S DISEASE (CD) IN REAL LIFE: SUSTAIN STUDY

Javier Pérez Gisbert  et al.

Item 1 - 4 / 4
1